These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38295233)

  • 1. Cardiotoxicity Associated with Antihuman Epidermal Growth Factor Receptor-2 Therapy: Particular Aspects of a Specific Phenomenon.
    Yalta K
    Anatol J Cardiol; 2024 Feb; 28(2):128-129. PubMed ID: 38295233
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Letter to the Editor: 'Cardiotoxicity Associated with Antihuman Epidermal Growth Factor Receptor-2 Therapy: Particular Aspects of a Specific Phenomenon'.
    Şener YZ; Ardalı Düzgün S; Hazırolan T; Tokgözoğlu L
    Anatol J Cardiol; 2024 Feb; 28(2):130-131. PubMed ID: 38295234
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients.
    Leemasawat K; Phrommintikul A; Chattipakorn SC; Chattipakorn N
    Cell Mol Life Sci; 2020 Apr; 77(8):1571-1589. PubMed ID: 31650186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman.
    Alghafar DA; Younos I; Baimani KA; Al-Salhi D; Al-Riyami A; Rizvi S; Buckley NE
    J Oncol Pharm Pract; 2021 Mar; 27(2):312-321. PubMed ID: 32340535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
    He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
    Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
    BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab cardiotoxicity: from clinical trials to experimental studies.
    Nemeth BT; Varga ZV; Wu WJ; Pacher P
    Br J Pharmacol; 2017 Nov; 174(21):3727-3748. PubMed ID: 27714776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
    Schneider JW; Chang AY; Rocco TP
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity.
    Anjos M; Fontes-Oliveira M; Costa VM; Santos M; Ferreira R
    Life Sci; 2021 Sep; 280():119760. PubMed ID: 34166713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
    Litvak A; Batukbhai B; Russell SD; Tsai HL; Rosner GL; Jeter SC; Armstrong D; Emens LA; Fetting J; Wolff AC; Silhy R; Stearns V; Connolly RM
    Cancer; 2018 May; 124(9):1904-1911. PubMed ID: 29381193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab-induced cardiotoxicity in early breast cancer over a 10-year period in Uruguay.
    Castillo C; Camejo N; Etcheverria C; Ferradaz J; Ferreira A; Fontan A; Gabin AS; Herrera G; Artagaveytia N; Parma G; Delgado L
    Medicine (Baltimore); 2022 Jul; 101(30):e29927. PubMed ID: 35905268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study.
    Feng Y; Qin Z; Yang Z
    J Clin Pharm Ther; 2021 Feb; 46(1):93-98. PubMed ID: 32975332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Concomitant radiotherapy and trastuzumab: Rational and clinical implications].
    Fourati N; Trigui R; Charfeddine S; Dhouib F; Kridis WB; Abid L; Khanfir A; Mnejja W; Daoud J
    Bull Cancer; 2021 May; 108(5):501-512. PubMed ID: 33745737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
    Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
    J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab.
    Sendur MA; Aksoy S; Altundag K
    Future Oncol; 2015; 11(1):13-5. PubMed ID: 25572781
    [No Abstract]   [Full Text] [Related]  

  • 17. Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer.
    Grazziotin LR; Picon PD
    J Oncol Pharm Pract; 2017 Jun; 23(4):264-272. PubMed ID: 26983449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab and Doxorubicin Sequential Administration Increases Oxidative Stress and Phosphorylation of Connexin 43 on Ser368.
    Pecoraro M; Marzocco S; Franceschelli S; Popolo A
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients.
    Aitelhaj M; Lkhouyaali S; Rais G; Mohtaram A; Raissouni S; Ghissassi B; Boutayeb S; Mrabti H; Bensouda Y; Errihani H
    BMC Res Notes; 2013 Aug; 6():339. PubMed ID: 23985308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.